Which of the following panels is appropriate for assessing hypercoagulability?

The assessment of hypercoagulability often requires a comprehensive evaluation of factors that influence clot formation and breakdown in the body. The correct choice involves not only standard coagulation tests but also specific evaluations for potential risk factors related to thrombosis.

The inclusion of lupus anticoagulant screening within this panel is particularly significant. Lupus anticoagulant is an antibody associated with an increased risk of thrombosis, and its presence can contribute to a hypercoagulable state. Testing for lupus anticoagulant helps in identifying one of the key autoimmune factors that can predispose individuals to venous and arterial clots.

Other components, such as PT (Prothrombin Time) and aPTT (Activated Partial Thromboplastin Time), provide important insights into the overall functionality of the coagulation pathways. While these tests help assess the clotting ability of the blood and can indicate if there is an issue with clotting factors, they do not address the specific mechanisms of hypercoagulability as thoroughly as the inclusion of lupus anticoagulant screening does.

In contrast, the other options may incorporate useful tests but lack essential evaluations pertinent to hypercoagulable states. For example, while PT, aPTT, and d-dimer screening can indicate clot breakdown